- Home
- AGMH vs AEMD Comparison
AGMH vs AEMD Comparison
Compare AGMH & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | AEMD |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AGMH | AEMD |
|---|---|---|
| Price | $1.09 | $0.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 46.4K | ★ 196.1K |
| Earning Date | 05-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.51 |
| 52 Week High | $18.10 | $5.89 |
Technical Indicators
Market Signals| Indicator | AGMH | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 24.92 |
| Support Level | $1.01 | $0.64 |
| Resistance Level | $1.38 | $0.83 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 47.30 | 6.47 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.